Research by Gosia Kuran, Lead MS Nurse Specialist, King’s College Hospital

All of our attendees carry out a piece of research in an area of MS clinical practice or treatment that interests them. 

This snapshot gives you a quick idea of what they found and why. If you want to learn more, just click through to the full poster, or follow the links within the snapshot. 

If you would like to contact the alumni who did the research, drop us a line and we’ll put you in touch where possible.

Poster

Gosia-Kuran-poster

Aim

To review the impact of the COVID-19 pandemic on King’s College Hospital’s ocrelizumab infusion service with a view to restarting and developing it.

Headlines 

  • Before the pandemic, the ocrelizumab service at King’s was running three times a week, with a capacity for 12 patients
  • When the service was suspended, on 20 March 2020, the average wait time for therapy was 12 to 16 weeks
  • By June 2020, 206 patients (64 new and 142 previously treated) were awaiting therapy 
  • Among the 142 previously treated patients, the delay varied from three weeks to five months 

Key findings 

To reinstate the service, the team:

  • Flagged the urgent need to service managers
  • Worked to make the supplied space suitable for the service – this included working with other departments to secure equipment and deep cleaning or de-cluttering 
  • Produced a standard operating procedure 
  • Adopted strict infection control and isolation procedures
  • Implemented an MDT-managed traffic light system to prioritise patients in order of clinical need
  • Implemented urgent MS nurse clinics to rescreen patients before re-starting treatment 

The unit reopened on 13 July 2020. As of 23 October 2020:

  • 175 patients (41 new and 143 previously treated) have received treatment at the King’s unit
  • 13 have had their care repatriated to local MS services
  • 18 decided not to start or continue therapy due to concern over COVID-19 risk

There is currently no waiting list.

Recommendations 

The review demonstrated the need for a complete redesign of the ocrelizumab infusion service in the light of the COVID-19 pandemic.

Take action

View the poster or contact her to discuss the work (please put the name of the Snapshot as your title in our contact form)